ShockWave Medical (SWAV) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

SWAV Stock Forecast

ShockWave Medical stock forecast is as follows: an average price target of $258.17 (represents a -22.88% downside from SWAV’s last price of $334.75) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.

SWAV Price Target

The average price target for ShockWave Medical (SWAV) is $258.17 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $360.00 to $175.00. This represents a potential -22.88% downside from SWAV's last price of $334.75.

SWAV Analyst Ratings

Hold

According to 10 Wall Street analysts, ShockWave Medical's rating consensus is 'Hold'. The analyst rating breakdown for SWAV stock is 0 'Strong Buy' (0.00%), 1 'Buy' (10.00%), 8 'Hold' (80.00%), 1 'Sell' (10.00%), and 0 'Strong Sell' (0.00%).

ShockWave Medical Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 05, 2024	William Plovanic	Johnson Rice	$335.00	$325.48	2.92%	0.07%
Apr 02, 2024	Adam Maeder	Piper Sandler	$360.00	$320.51	12.32%	7.54%
Jan 06, 2023	-	Morgan Stanley	$224.00	$208.17	7.60%	-33.08%
Aug 29, 2022	-	Piper Sandler	$338.00	$304.44	11.02%	0.97%
Aug 09, 2022	-	Morgan Stanley	$255.00	$258.93	-1.52%	-23.82%
Aug 09, 2022	-	Wells Fargo	$255.00	$221.77	14.98%	-23.82%
Aug 09, 2022	-	Piper Sandler	$278.00	$221.77	25.36%	-16.95%
Jul 15, 2022	-	Morgan Stanley	$201.00	$209.90	-4.24%	-39.96%
May 10, 2022	-	Morgan Stanley	$180.00	$133.39	34.94%	-46.23%
May 10, 2022	-	Wells Fargo	$176.00	$115.91	51.84%	-47.42%

Row per page

Go to

The latest ShockWave Medical stock forecast, released on Apr 05, 2024 by William Plovanic from Johnson Rice, set a price target of $335.00, which represents a 2.92% increase from the stock price at the time of the forecast ($325.48), and a 0.07% increase from SWAV last price ($334.75).

ShockWave Medical Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$347.50
Last Closing Price	$334.75	$334.75	$334.75
Upside/Downside	-100.00%	-100.00%	3.81%

In the current month, the average price target of ShockWave Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ShockWave Medical's last price of $334.75. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
May 09, 2024	Wells Fargo	Equal-Weight	Equal-Weight	Hold
Apr 08, 2024	Morgan Stanley	Overweight	Equal-Weight	Downgrade
Apr 08, 2024	Johnson Rice	Market Perform	Neutral	Downgrade
Apr 05, 2024	Johnson Rice	Hold	Market Perform	Downgrade
Apr 05, 2024	Johnson Rice	-	Hold	Downgrade
Apr 05, 2024	Piper Sandler	Overweight	Neutral	Downgrade
Apr 05, 2024	Needham	Buy	Hold	Downgrade
Apr 04, 2024	Wolfe Research	-	Peer Perform	Downgrade
Mar 27, 2024	Piper Sandler	Overweight	Overweight	Hold
Oct 24, 2023	Needham	Buy	Buy	Hold

Row per page

Go to

ShockWave Medical's last stock rating was published by Wells Fargo on May 09, 2024. The company gave SWAV a "Equal-Weight" rating, the same as its previous rate.

ShockWave Medical Financial Forecast

ShockWave Medical Revenue Forecast

	Dec 26	Oct 26	Jul 26	Mar 26	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$202.98M	-	-	$161.07M	$144.03M	-	-	$93.63M	$84.18M	-	-	$31.90M	$22.72M	-	-	$15.20M	$14.31M	-
Avg Forecast	$371.09M	$337.78M	$325.77M	$299.21M	$312.84M	$287.07M	$278.96M	$256.28M	$253.19M	$232.20M	$227.06M	$207.67M	$199.43M	$184.72M	$173.84M	$147.30M	$143.18M	$123.96M	$107.51M	$86.41M	$75.43M	$61.21M	$45.22M	$29.90M	$20.16M	$14.68M	$8.35M	$14.17M	$13.47M	$10.43M
High Forecast	$371.09M	$337.78M	$325.77M	$299.21M	$312.84M	$287.07M	$278.96M	$256.28M	$253.19M	$232.20M	$230.18M	$207.68M	$200.00M	$187.99M	$173.84M	$147.30M	$143.18M	$123.96M	$107.51M	$86.41M	$75.43M	$61.21M	$45.22M	$29.90M	$20.16M	$14.68M	$8.35M	$14.17M	$13.47M	$10.43M
Low Forecast	$371.09M	$337.78M	$325.77M	$299.21M	$312.84M	$287.07M	$278.96M	$256.28M	$253.19M	$232.20M	$225.28M	$207.66M	$199.10M	$182.70M	$173.84M	$147.30M	$143.18M	$123.96M	$107.51M	$86.41M	$75.43M	$61.21M	$45.22M	$29.90M	$20.16M	$14.68M	$8.35M	$14.17M	$13.47M	$10.43M
# Analysts	2	2	2	2	1	1	1	1	2	2	4	3	6	10	5	5	4	4	4	4	5	5	5	5	5	5	5	5	4	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.02%	-	-	1.09%	1.01%	-	-	1.08%	1.12%	-	-	1.07%	1.13%	-	-	1.07%	1.06%	-

ShockWave Medical's average Quarter revenue forecast for Mar 24 based on 3 analysts is $207.67M, with a low forecast of $207.66M, and a high forecast of $207.68M. SWAV's average Quarter revenue forecast represents a 2.31% increase compared to the company's last Quarter revenue of $202.98M (Dec 23).

ShockWave Medical EBITDA Forecast

	Dec 26	Oct 26	Jul 26	Mar 26	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19
# Analysts	2	2	2	2	1	1	1	1	2	2	4	3	6	10	5	5	4	4	4	4	5	5	5	5	5	5	5	5	4	4
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$46.36M	-	-	$41.37M	$45.62M	-	-	$16.73M	$15.02M	-	-	$-22.12M	$-296.87K	-	-	$-17.68M	$-13.85M	-
Avg Forecast	$-110.63M	$-100.70M	$-97.12M	$-89.20M	$-93.27M	$-85.59M	$-83.17M	$-76.40M	$-75.48M	$-69.23M	$-67.70M	$18.68M	$-59.46M	$-55.07M	$-51.83M	$16.98M	$42.47M	$-36.96M	$-32.05M	$15.44M	$-22.49M	$-18.25M	$-13.48M	$-11.90M	$-6.01M	$-4.38M	$-2.49M	$-14.07M	$-4.02M	$-3.11M
High Forecast	$-110.63M	$-100.70M	$-97.12M	$-89.20M	$-93.27M	$-85.59M	$-83.17M	$-76.40M	$-75.48M	$-69.23M	$-67.17M	$22.42M	$-59.36M	$-54.47M	$-51.83M	$20.38M	$50.97M	$-36.96M	$-32.05M	$18.53M	$-22.49M	$-18.25M	$-13.48M	$-9.52M	$-6.01M	$-4.38M	$-2.49M	$-11.26M	$-4.02M	$-3.11M
Low Forecast	$-110.63M	$-100.70M	$-97.12M	$-89.20M	$-93.27M	$-85.59M	$-83.17M	$-76.40M	$-75.48M	$-69.23M	$-68.62M	$14.94M	$-59.63M	$-56.05M	$-51.83M	$13.59M	$33.98M	$-36.96M	$-32.05M	$12.35M	$-22.49M	$-18.25M	$-13.48M	$-14.27M	$-6.01M	$-4.38M	$-2.49M	$-16.89M	$-4.02M	$-3.11M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-0.78%	-	-	2.44%	1.07%	-	-	1.08%	-0.67%	-	-	1.86%	0.05%	-	-	1.26%	3.45%	-

3 analysts predict SWAV's average Quarter EBITDA for Mar 24 to be $18.68M, with a high of $22.42M and a low of $14.94M. This is -59.70% lower than ShockWave Medical's previous annual EBITDA (Dec 23) of $46.36M.

ShockWave Medical Net Income Forecast

	Dec 26	Oct 26	Jul 26	Mar 26	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19
# Analysts	2	2	2	2	1	1	1	1	2	2	4	3	6	10	5	5	4	4	4	4	5	5	5	5	5	5	5	5	4	4
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$44.30M	-	-	$39.13M	$140.91M	-	-	$14.52M	$12.94M	-	-	$-23.60M	$-15.87K	-	-	$-18.77M	$-14.74M	-
Avg Forecast	$79.75M	$71.53M	$68.63M	$61.49M	$68.60M	$62.06M	$59.63M	$54.59M	$58.07M	$49.69M	$45.16M	$16.21M	$34.25M	$29.98M	$31.87M	$14.74M	$36.61M	$25.72M	$17.06M	$13.40M	$3.28M	$-2.19M	$-15.33M	$-12.69M	$-16.30M	$-21.28M	$-23.91M	$-14.94M	$-19.73M	$-19.62M
High Forecast	$79.75M	$71.53M	$68.63M	$61.49M	$68.60M	$62.06M	$59.63M	$54.59M	$58.07M	$49.69M	$55.07M	$19.45M	$43.55M	$36.81M	$31.87M	$17.68M	$43.93M	$25.72M	$17.06M	$16.08M	$3.28M	$-2.19M	$-15.33M	$-10.15M	$-16.30M	$-21.28M	$-23.91M	$-11.95M	$-19.73M	$-19.62M
Low Forecast	$79.75M	$71.53M	$68.63M	$61.49M	$68.60M	$62.06M	$59.63M	$54.59M	$58.07M	$49.69M	$42.59M	$12.97M	$30.90M	$24.29M	$31.87M	$11.79M	$29.29M	$25.72M	$17.06M	$10.72M	$3.28M	$-2.19M	$-15.33M	$-15.23M	$-16.30M	$-21.28M	$-23.91M	$-17.93M	$-19.73M	$-19.62M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.29%	-	-	2.66%	3.85%	-	-	1.08%	3.94%	-	-	1.86%	0.00%	-	-	1.26%	0.75%	-

ShockWave Medical's average Quarter net income forecast for Mar 24 is $16.21M, with a range of $12.97M to $19.45M. SWAV's average Quarter net income forecast represents a -63.41% decrease compared to the company's last Quarter net income of $44.30M (Dec 23).

ShockWave Medical SG&A Forecast

	Dec 26	Oct 26	Jul 26	Mar 26	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19
# Analysts	2	2	2	2	1	1	1	1	2	2	4	3	6	10	5	5	4	4	4	4	5	5	5	5	5	5	5	5	4	4
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$92.06M	-	-	$73.22M	$60.38M	-	-	$48.35M	$42.82M	-	-	$31.22M	$23.07M	-	-	$16.64M	$14.05M	-
Avg Forecast	$271.80M	$247.41M	$238.61M	$219.16M	$229.14M	$210.26M	$204.32M	$187.71M	$185.45M	$170.07M	$166.31M	$53.97M	$146.07M	$135.29M	$127.33M	$49.07M	$121.12M	$90.80M	$78.75M	$44.61M	$55.25M	$44.83M	$33.12M	$16.79M	$14.76M	$10.75M	$6.11M	$13.24M	$9.87M	$7.64M
High Forecast	$271.80M	$247.41M	$238.61M	$219.16M	$229.14M	$210.26M	$204.32M	$187.71M	$185.45M	$170.07M	$168.60M	$64.77M	$146.49M	$137.70M	$127.33M	$58.88M	$145.34M	$90.80M	$78.75M	$53.53M	$55.25M	$44.83M	$33.12M	$20.15M	$14.76M	$10.75M	$6.11M	$15.89M	$9.87M	$7.64M
Low Forecast	$271.80M	$247.41M	$238.61M	$219.16M	$229.14M	$210.26M	$204.32M	$187.71M	$185.45M	$170.07M	$165.01M	$43.18M	$145.83M	$133.82M	$127.33M	$39.25M	$96.90M	$90.80M	$78.75M	$35.68M	$55.25M	$44.83M	$33.12M	$13.43M	$14.76M	$10.75M	$6.11M	$10.59M	$9.87M	$7.64M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.63%	-	-	1.49%	0.50%	-	-	1.08%	0.78%	-	-	1.86%	1.56%	-	-	1.26%	1.42%	-

ShockWave Medical's average Quarter SG&A projection for Mar 24 is $53.97M, based on 3 Wall Street analysts, with a range of $43.18M to $64.77M. The forecast indicates a -41.37% fall compared to SWAV last annual SG&A of $92.06M (Dec 23).

ShockWave Medical EPS Forecast

	Dec 26	Oct 26	Jul 26	Mar 26	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19
# Analysts	2	2	2	2	1	1	1	1	2	2	4	3	6	10	5	5	4	4	4	4	5	5	5	5	5	5	5	5	4	4
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$1.16	-	-	$1.07	$3.89	-	-	$0.41	$0.37	-	-	$-0.68	$-0.00	-	-	$-0.59	$-0.49	-
Avg Forecast	$2.07	$1.86	$1.78	$1.60	$1.78	$1.61	$1.55	$1.42	$1.51	$1.29	$1.17	$0.99	$0.89	$0.78	$0.83	$0.79	$1.01	$0.67	$0.44	$0.18	$0.09	$-0.06	$-0.40	$-0.45	$-0.42	$-0.55	$-0.62	$-0.49	$-0.51	$-0.51
High Forecast	$2.07	$1.86	$1.78	$1.60	$1.78	$1.61	$1.55	$1.42	$1.51	$1.29	$1.43	$0.99	$1.13	$0.96	$0.83	$0.79	$1.01	$0.67	$0.44	$0.18	$0.09	$-0.06	$-0.40	$-0.45	$-0.42	$-0.55	$-0.62	$-0.49	$-0.51	$-0.51
Low Forecast	$2.07	$1.86	$1.78	$1.60	$1.78	$1.61	$1.55	$1.42	$1.51	$1.29	$1.11	$0.99	$0.80	$0.63	$0.83	$0.79	$1.01	$0.67	$0.44	$0.18	$0.09	$-0.06	$-0.40	$-0.45	$-0.42	$-0.55	$-0.62	$-0.49	$-0.51	$-0.51
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.30%	-	-	1.35%	3.86%	-	-	2.23%	4.34%	-	-	1.52%	0.00%	-	-	1.20%	0.96%	-

According to 3 Wall Street analysts, ShockWave Medical's projected average Quarter EPS for Mar 24 is $0.99, with a low estimate of $0.99 and a high estimate of $0.99. This represents a -14.72% decrease compared to SWAV previous annual EPS of $1.16 (Dec 23).

ShockWave Medical Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
OM	Outset Medical	$0.76	$11.00	1347.37%	Buy
TNDM	Tandem Diabetes Care	$30.74	$79.05	157.16%	Buy
ALGN	Align	$228.21	$421.00	84.48%	Buy
TMDX	TransMedics Group	$79.34	$126.75	59.76%	Buy
NARI	Inari Medical	$49.75	$66.11	32.88%	Buy
INSP	Inspire Medical Systems	$186.19	$239.55	28.66%	Buy
EW	Edwards Lifesciences	$70.38	$88.04	25.09%	Buy
DXCM	DexCom	$74.46	$81.36	9.27%	Buy
CLPT	ClearPoint Neuro	$11.09	$12.00	8.21%	Buy
PODD	Insulet	$262.00	$274.00	4.58%	Buy
MASI	Masimo	$169.12	$161.83	-4.31%	Buy
PEN	Penumbra	$240.49	$224.85	-6.50%	Buy
SYK	Stryker	$390.14	$317.96	-18.50%	Buy
SWAV	ShockWave Medical	$334.75	$258.17	-22.88%	Hold

SWAV Forecast FAQ

Is ShockWave Medical a good buy?

No, according to 10 Wall Street analysts, ShockWave Medical (SWAV) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 10.00% of SWAV's total ratings.

What is SWAV's price target?

ShockWave Medical (SWAV) average price target is $258.17 with a range of $175 to $360, implying a -22.88% from its last price of $334.75. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will ShockWave Medical stock go up soon?

According to Wall Street analysts' prediction for SWAV stock, the company can go down by -22.88% (from the last price of $334.75 to the average price target of $258.17), up by 7.54% based on the highest stock price target, and down by -47.72% based on the lowest stock price target.

Can ShockWave Medical stock reach $500?

SWAV's average twelve months analyst stock price target of $258.17 does not support the claim that ShockWave Medical can reach $500 in the near future.

What are ShockWave Medical's analysts' financial forecasts?

ShockWave Medical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.14B (high $1.14B, low $1.14B), average EBITDA is $-338M (high $-338M, low $-338M), average net income is $244.88M (high $244.88M, low $244.88M), average SG&A $831.44M (high $831.44M, low $831.44M), and average EPS is $6.37 (high $6.37, low $6.37). SWAV's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.33B (high $1.33B, low $1.33B), average EBITDA is $-398M (high $-398M, low $-398M), average net income is $281.41M (high $281.41M, low $281.41M), average SG&A $976.98M (high $976.98M, low $976.98M), and average EPS is $7.31 (high $7.31, low $7.31).

Did the SWAV's actual financial results beat the analysts' financial forecasts?

Based on ShockWave Medical's last annual report (Dec 2023), the company's revenue was $730.23M, beating the average analysts forecast of $705.28M by 3.54%. Apple's EBITDA was $169.45M, missing the average prediction of $-149M by -213.44%. The company's net income was $147.28M, beating the average estimation of $110.83M by 32.88%. Apple's SG&A was $330.1M, missing the average forecast of $457.76M by -27.89%. Lastly, the company's EPS was $3.85, beating the average prediction of $3.29 by 16.95%. In terms of the last quarterly report (Dec 2023), ShockWave Medical's revenue was $202.98M, beating the average analysts' forecast of $199.43M by 1.78%. The company's EBITDA was $46.36M, missing the average prediction of $-59.457M by -177.97%. ShockWave Medical's net income was $44.3M, beating the average estimation of $34.25M by 29.37%. The company's SG&A was $92.06M, missing the average forecast of $146.07M by -36.98%. Lastly, the company's EPS was $1.16, beating the average prediction of $0.89 by 30.31%